axon call rap littl bit ago compani report result even stori hat
ahead expect manag optimist outlook overal abil gain share see increas market
overal ith new technolog mri compat recharg reiter overw eight rate
takeaw ay call
endors consensu revenu expect hen ask view consensu revenu estim
 hich ere cite us cite manag acknow ledg cite intend
make note noth easi ere lay-up agre
easi target estim ould impli full year share ever believ achiev level given
alreadi establish commerci sale forc full label indic manag note ould like give formal
guidanc full quarter belt hich ould expect stub
period first commerci implant fda approv urinari indic came last night also keep mind
holiday ell there lot opportun get peopl calendar physician ere ait get
indic approv sign peopl surgeri net/net iew com entari positiv
shelf file good housekeep ere coupl question cash balanc potenti addit rais
manag note put shelf year ipo ould opportunist manag note
equival short term invest total sept enough fund launch
continu market
 oo stew bloomberg im email call kristen
 ant inform axon see initi report address innov void initi ith overw eight rate
follow -up readi set go oab day physician seminar takeaw ay reit ow
sinc last call august axon make excel progress
commerci team market product unit state albeit limit basi
despit anticip slow dow high volum center europ saw momentum intern busi ith new account
germani sw itzerland bring number ou custom
see case bounc back account got back on-line summer break season play role ith
first commerci case octob uc irvin oct dr lane
fda approv oab urinari retent receiv last night
net revenu total million intern market hich compar year ago
revenu primarili sale rsnm european market hospit account canada
ship product us quarter
gross profit gross margin note ill like move around manufactur ramp anticip margin improv
 ith volum scale pleas ith
equival short term invest total sept increas opex driven personnel cost
build commerci infrastructur market prep launch infrastructur manufactur oper public
compani acceler number program readi fda approv hire train commerci team sale
profession manufactur qualiti system regulatori activ ere commit launch activ commerci team
hire train readi hit ground run abl ork typic oper grow ing pain prior ship first
sale market combin ith oper cost opex line ramp quarter quarter ever pattern
stabil
anticip opex remain current level mid-year ill focu sg spend best return primari
focu secur account us look account account basi
feedback physician patient confirm axon thesi expect compet market becom
expect continu grow th oversea market low er volum us
ou ou hospit implant r-snm system hospit england netherland germani
sw itzerland canada time hand exclus de novo patient mention
market small capit term money avail point canada system
liter ran budget money
us fda approv urinari critic mileston took month get fda approv anoth month second
execut full launch commerci team detail data clinic data critic import physician
base survey conduct seminar seri efficaci list primari reason select product anoth
featur benefit system full bodi mri procedur program support price system least import
earli octob augs/iuga nashvil collect interest physician symposium physician octob
held first physician seminar sinc addit implant fifth ad atlanta accommod
overflow demand experienc implant ill attend
commerci team consist total individu
ramp inventori support goal market leadership
ip lawsuit axon develop ow ip estat claim assert frivol parti involv treat patient
devot resourc tow ard innov treat patient rais aw are market
new product development- anticip next-gener devic extend recharg time period
month approv expect non-recharg devic expect
question answer question manag respons verbatim
street want investor think busi comment
consensu fair say comfort ith project go unit state put number board
noth easi lay-up axon confid compani fulli intend make number
short run difficult answ er gotten start ship take order procedur
 eek sale forc enthusiast respons that go ell honestli custom ait
urinari approv vast major case book date fecal incontin dual case need mri
physician commun disciplin physician cautiou physician hospit need get paid
consciou hat happen background
feel like backlog think think time novemb there
day procedur novemb holiday there day holiday
enthusiasm among physician patient line abil get book right
betw een end year challeng go hat manag know hat consensu number
number us ou intent beat number think logist involv trial
also get perman implant
consensu form analyst werent expect competitor still case irrespect
 hat happen ith new product launch interest fact physician ant use product also
expans market account account basi patient ill say ye devic recharg
devic improv qualiti life
guidanc said need get quarter belt ould better posit say hat go come
next quarter go posit reaffirm guid differ ay januari ill happen first
quarter ill shi say hat ill think busi philosophi open book
anyth need launch oab noth compliant ith post-approv requir
 ere knock septemb octob ship sinc
plan integr product practic custom interest ork ith
incumb case old lead remov axon put
cost litig time play seem take forev play rel new talk attorney
process take long money intern budget cover litig cost cost plan substanti
natur ould break
competit chang quarter price axon strategi match price market place
 hat chang axon believ got skin peopl minneapoli put press releas new product
file law suit seem thing field ith talk track abl ship product injunct around product
manag think ill backfir axon manag note market year
competit part market axon happi compet
gener compat lead time second gener devic clinic studi
 ill requir manag note ould like note compress fda timelin axon
histori show ay short cut
stock put stock shelv custom order hat need implant patient next eek
interest put stock shelv easi busi ith ill give good price dont big order get
good price
efficaci physician follow -up survey physician seminar indic efficaci key takeaw ay
relat constant current vs constant voltag debat
find survey physician talk mani today say ell im
 sacral neuromodul devic botox say optimist ill
recharg mri product axon thing could snm could done physician confid
sens doctor physician seminar percent volum repres
consider percentag last meet occur focus thing invite ere among
among volum signific amount
market growth somewher mid-singl digit base convers physician
reason assumpt said axon think market ill doubl next year physician think
market grow th go better overal think market go grow faster rate hat grow
past ith addit new technolog market
shelf registr cash access file one year year good housekeep compani
million cash equival fund launch market
balanc sheet shelf would take look launch go look rais file
option ant opportunist thing evolv landscap complet differ tw day ago eek
ago thing happen ill tri opportunist
manufactur capac meet demand inventori increas product volum build plan
finish good ahead come quarter plan us commerci launch sever month
gross margin rang time neuromodul product could get hat messag
invest commun scale gross margin could low mid manag see leverag busi
 hen get oper expens line straight forw ard procedur lot postop follow -up
leverag
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
